<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136551</url>
  </required_header>
  <id_info>
    <org_study_id>HUPA - CR- HMO-CTIL</org_study_id>
    <secondary_id>HUPA-HU-1</secondary_id>
    <nct_id>NCT01136551</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A</brief_title>
  <official_title>An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop oral controlled release formulation of Huperzine A
      that will provide optimal pharmacokinetic profile of the drug enhancing safety and
      compliance, as possible cure to neurodegenerative disorders.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Huperzine A different formulations</measure>
    <time_frame>Blood samples will be taken for 36 hours after Huperzine A administration</time_frame>
    <description>Pharmacokinetic parameters: C max, T max, AUC, t1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events. Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events.</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy</condition>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>IR formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR formulation
Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR formulation
Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huperzine A</intervention_name>
    <description>Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.</description>
    <arm_group_label>IR formulation</arm_group_label>
    <arm_group_label>CR 1</arm_group_label>
    <arm_group_label>CR 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males between the age of 18 and 35, inclusive (ASA = 1)

          2. Body weight &gt; 50 kg

          3. Subject has a BMI less than 27 and more than 20

          4. Participants should be able to ingest oral medication

          5. The ability to understand and sign a written informed consent form, prior to
             participation and the willingness to comply with all study requirements

        Exclusion Criteria:

          1. History of drug sensitivity or drug allergy

          2. History of sensitivity to eggs

          3. Subject has a BMI less than 20 and more than 27

          4. Previous participation in an investigational trial involving administration of any
             investigational compound within 1 month prior to the current study

          5. History of alcoholism or drug addiction

          6. Any medication taken including over-the-counter medications and herbal products within
             14 days of commencing study drug dosing with the exception of vitamins and/or
             paracetamol. When a concomitant medication is necessary, this will be reviewed by the
             investigator and if not contraindicated, may be continued at the same dose and
             frequency during the study period

          7. History of clinically important illness (ASA&gt;1); Disorders or conditions that could
             affect the absorption, distribution, metabolism and/or excretion of drugs (e.g.
             malabsorption, edema, renal or hepatic insufficiency)

          8. Inability to relate to and/or cooperate with the investigators

          9. Blood loss or donation greater than 200ml in the 3 months prior to the trial

         10. Exhausting physical exercise during the previous 48 hours to drug administration

         11. Subjects who have smoked or used nicotine-containing products within 6 months prior to
             study entry
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Friedman, Proffesor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Drug Research, Hebrew University of Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregory Burshtein, MA</last_name>
    <phone>97226758665/4</phone>
    <email>bursht@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliad Davidson, MD</last_name>
      <phone>97226776911</phone>
      <email>edavidson@hadassah.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>June 2, 2010</last_update_submitted>
  <last_update_submitted_qc>June 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Eliad Davidson, MD</name_title>
    <organization>School of pharmacy, Hebrew University of Jerusalem</organization>
  </responsible_party>
  <keyword>Pharmacokinetic profile of controlled release formulation of Huperzine A</keyword>
  <keyword>Bioequivalence of Huperzine A IR formulation and CR formulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huperzine A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

